eligibility_summary
Inclusion: Adults 18–70 with histo/cyto-confirmed CRC, ≥1 measurable lesion, progressed after standard 2nd-line (≥2 wks since last therapy), ECOG 0–1, expected survival ≥3 mo, adequate organ/hematologic function, normal endocrine/rheum labs, no active infections, consent, women: negative pregnancy test and contraception. Exclusion: uncontrolled brain mets, need other anticancer therapy, recent steroids/immunotherapy/trials, major CV/uncontrolled HTN, bleeding/thrombosis, active infection/TB, transplant, CNS disorders, splenectomy, pregnancy/lactation, severe allergy, substance abuse, or investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06751966 (CRC after second-line failure) tests: 1) Personalized tumor neoantigen-based peptide vaccine (therapeutic peptide vaccine, s.c.) plus 2) conventional third-line therapy (oral chemotherapy and/or targeted agents, physician-selected). Mechanisms: The vaccine uses patient-specific mutated peptides (from tumor exome/RNA-seq and HLA typing). Peptides are taken up by antigen-presenting cells and displayed via HLA I/II to prime/boost neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells, enabling tumor-specific killing and immune memory. Targets/pathways: dendritic cells/APCs, TCR–HLA antigen-presentation pathway, CTLs directed at CRC cells expressing the selected neoantigens. Conventional therapy MOA varies by drug.